Loading clinical trials...

Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT

Use of Duloxetine for Perioperative Pain Control After Total Hip Arthroplasty: Randomized Controlled Clinical Trial (RCT)

NCT06807866•University of Miami

View on ClinicalTrials.gov

Summary

The primary objective of this study is to compare total narcotic intake standardized via milligram morphine equivalents between duloxetine and placebo cohorts after a total hip arthroplasty.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients \> 18 years of age
•Patients undergoing primary total hip arthroplasty
•Ambulatory patient prior to fracture
•Subjects must be capable of providing informed consent
•English or Spanish speaking

Exclusion Criteria

•Previous hemiarthroplasty or THA on ipsilateral hip
•History of Complex Regional Pain Syndrome in ipsilateral extremity
•History of demyelinating disorder or neurologic deficit that may contribute to altered pain tolerance or sensation
•Acute or chronic hip infection in ipsilateral extremity
•Pregnant or breastfeeding
•Open fracture
•Polytrauma
•Intravenous or drug users within 6 months of surgery
•Liver Failure via clinical diagnosis or international normalized ratio greater than 1.5 or partial thromboplastin time greater than 40
•Patients on selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitor, and/or tricyclic anti-depressant
+4 more criteria

Locations (1)

University of Miami

Miami, Florida, United States

Key Dates

Start Date

March 1, 2025

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

March 18, 2026

Enrollment

ESTIMATED participants

Conditions

THA

Interventions

Duloxetine

DRUG

Placebo

OTHER

Contacts

Victor Hernandez, MD

CONTACT

3056895195 vhh1@miami.edu

Natalia Cruz, MD

CONTACT

3056895195 nxc971@miami.edu

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799

Methamphetamine-dependenceMethamphetamine Abuse

View study

RECRUITINGNA

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

NCT05689463

Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT

Inclusion Criteria

Exclusion Criteria

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Molecular Mechanisms Underlying Hip and Knee Osteoarthritis in Patients Undergoing Primary Elective Arthroplasty